# A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

> **NCT05507580** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 461 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT05507580
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-29
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-08-15
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507580, "A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05507580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*